NXP900 Clinical Trials (2026): 2 Studies for Advanced Solid Tumor & EGFR Mutated Non-small Cell Lung Cancer Patients
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 NXP900 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Advanced Solid Tumor & EGFR Mutated Non-small Cell Lung Cancer Patients) and 158 total planned enrollment. 2 NXP900 clinical trials are actively recruiting at 12 U.S. sites across 8 states. Most recent activity: NCT05873686 (Jul 2027).
Where to Participate: All NXP900 Trial Sites in the U.S. (12 sites across 8 states)
Every actively recruiting NXP900trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Mayo Clinic | Phoenix85054 | NCT05873686 | Map |
| CO | Sarah Cannon Research Institute at HealthONE | Denver80218 | NCT05873686 | Map |
| FL | Mayo Clinic | Jacksonville32224 | NCT05873686 | Map |
| IL | University of Chicago | Chicago60637 | NCT05873686 | Map |
| MN | Mayo Clinic Rochester | Rochester55905 | NCT05873686 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT05873686 | Map |
| TX | NEXT Houston | Houston77054 | NCT07315113 | Map |
| TX | NEXT Oncology Houston | Houston77054 | NCT05873686 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT05873686 | Map |
| TX | NEXT Oncology Dallas | Irving75039 | NCT05873686 | Map |
| VA | NEXT Oncology Virginia | Fairfax22031 | NCT05873686 | Map |
| VA | NEXT Virginia | Fairfax22031 | NCT07315113 | Map |
NXP900 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 2 | 2 |
Recruiting NXP900 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05873686 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | P1 | Advanced Solid Tumor | 140 | Oct 2023 |
| NCT07315113 | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | P1 | EGFR Mutation Positive Non-small Cell Lung Cancer | 18 | Dec 2025 |
NXP900 clinical trials by indication
EGFR Mutation Positive Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07315113 | — | P1 | recruiting | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer |
Advanced Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05873686 | — | P1 | recruiting | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers |
All NXP900 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05873686 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | P1 | recruiting | 140 | Nuvectis Pharma, Inc. | Oct 2023 | |
| NCT07315113 | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | P1 | recruiting | 18 | Nuvectis Pharma, Inc. | Dec 2025 |
NXP900 clinical trials: frequently asked questions
- How many NXP900 clinical trials are there?
- 2 NXP900 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are NXP900 clinical trials recruiting in 2026?
- Yes — 2 NXP900 trials are actively recruiting in 2026, with 12 U.S. sites across 8 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is NXP900 being studied for?
- NXP900 is being studied for Advanced Solid Tumor, EGFR Mutated Non-small Cell Lung Cancer Patients, EGFR Mutation Positive Non-small Cell Lung Cancer, Mesothelioma, Non-small Cell Lung Adenocarcinoma and 3 more. The trials are grouped by indication on this page.
- What phase is NXP900 in?
- NXP900 clinical trials span 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors NXP900 clinical trials?
- The lead sponsor across the most NXP900 trials is Nuvectis Pharma, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming NXP900as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: